62
/ 2
Min Read
Alkem Laboratories is preparing to strengthen its position in India's chronic care pharmaceutical market, with newly appointed Chief Executive Officer Amrut Naik identifying diabetes, cardiovascular, neuropsychiatry and dermatology as key growth areas. The Mumbai-based drugmaker plans to increase the contribution of chronic therapies to its overall product portfolio as it looks to capture a larger share of India's evolving healthcare market.
Speaking to analysts after the company's second-quarter FY27 results, Naik said, “building the chronic franchise is going to be very critical for us. Today, it accounts for 24 per cent - 25 per cent of the total mix, compared to the industry, which is at about 65/35 (acute/chronic). So, gaining market share in chronic is going to be very critical.”
Alkem has traditionally maintained a strong presence in acute therapies, including antibiotics, antacids and pain management. However, the new strategy signals a greater focus on treatments for long-term conditions, particularly as demand for diabetes and cardiovascular medicines continues to grow in India.
Anti-diabetic and cardiovascular therapies will remain immediate priorities, while neuropsychiatry and dermatology are expected to provide additional opportunities. Commenting on the company's performance in semaglutide, Naik said, “despite cutthroat competition, Akem’s brand have been able to gain significant market share and will look to build on these gains.”
The company's chronic portfolio recorded 22.4 per cent growth during the September quarter, outperforming the broader Indian Pharmaceutical Market (IPM) by 640 basis points. Its domestic sales increased 9.5 per cent to Rs 3,027 crore, compared with Rs 2,766 crore in the corresponding period last year.
Alkem's overall revenue from operations reached Rs 4,552 crore in Q2 FY27, registering 13.8 per cent year-on-year growth.
Naik, who brings more than 26 years of pharmaceutical industry experience and previously held leadership positions at Zydus, Lupin and Ranbaxy, took charge as CEO on November 11, 2026. His immediate priority will be strengthening execution across the company's chronic care portfolio and improving market share across its represented therapies.
Source: ETPharma
